Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | APOEε4 carriership combined with Aβ positivity for AD clinical trial enrichment

Population enrichment is becoming increasingly recognized as a key element of Alzheimer’s disease (AD) clinical trials, in order to reduce required sample sizes and improve the chances of detecting a treatment effect. Amyloid-β (Aβ) pathology and the APOEε4 genotype have been shown to accelerate tau accumulation, however assessing both APOEε4 carriership and Aβ positivity as a strategy to enrich AD clinical trials has not yet been investigated. João Pedro Ferrari-Souza, MD-PhD student, University of Pittsburgh, Pittsburgh, PA, and his team investigated whether using both APOEε4 and Aβ positivity could reduce the sample size needed for clinical trials testing a 25% reduction in tau-PET accumulation. In total, 63 cognitively impaired individuals (Clinical Dementia Rating ≥ 0.5) from the McGill Translational Biomarkers in Aging and Dementia (TRIAD) cohort were studied. It was shown that to detect a 25% drug effect, using Aβ positivity plus APOEε4 carriership would require a sample size of 64% less than using Aβ positivity alone. In the future, Mr Ferrari-Souza wants to investigate whether these results are replicable in other cohorts and with other tau-PET tracers or measures of tau pathology such as plasma p-tau. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.